ACCUSTEM SCIENCES INC (ACUT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACUT SEC filings page.
This page shows ACCUSTEM SCIENCES INC (ACUT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Repeated operating losses and external financing support a business whose liabilities exceed its asset base.
FY2025 operating cash outflow was-$850K against a net loss of-$1.8M , so accounting losses were not fully reflected in current-period cash usage. The same financing pattern appeared in FY2022, when-$1.8M of operating cash outflow coincided with$2.6M of financing inflow, pointing to operations being funded from outside cash sources rather than internally generated cash.
The balance sheet moved from
With no reported revenue, FY2025 spending was concentrated in SG&A of
Financial Health Signals
ACCUSTEM SCIENCES INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ACCUSTEM SCIENCES INC passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
ACCUSTEM SCIENCES INC reported a net loss of $1.8M while operations used $850K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
ACCUSTEM SCIENCES INC generated $98K in revenue in Q2 2026.
ACCUSTEM SCIENCES INC reported -$253K in net income in Q2 2026. This represents an increase of 37.1% from the same quarter a year earlier. Against the prior quarter it is up 48.0%.
ACCUSTEM SCIENCES INC earned -$0.02 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 33.3%.
Not reported for Q2 2026.
Cash & Balance Sheet
ACCUSTEM SCIENCES INC held $13K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
ACCUSTEM SCIENCES INC invested $44K in research and development in Q2 2026. This represents a decrease of 27.4% from the same quarter a year earlier. Against the prior quarter it is down 63.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
ACUT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $98K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $44K-27.4% | $120K+321.7% | N/A | $73K+131.5% | $60K+44.2% | $28K+22.2% | N/A | $31K+57.4% |
| SG&A Expenses | $307K-9.9% | $366K-11.1% | N/A | $327K+10.2% | $341K+44.3% | $412K | N/A | $297K-48.7% |
| Operating Income | -$253K+37.1% | -$486K-10.3% | N/A | -$400K-21.9% | -$401K-44.3% | -$440K | N/A | -$328K+45.2% |
| EBITDA | N/A | N/A | N/A | -$400K-22.2% | -$401K-44.7% | -$440K | N/A | -$327K+45.2% |
| Net Income | -$253K+37.1% | -$486K-10.3% | N/A | -$400K-21.9% | -$401K-44.3% | -$440K | N/A | -$328K+45.2% |
| EPS (Basic) | -$0.020.0% | -$0.030.0% | -$0.04-33.3% | -$0.02+33.3% | -$0.020.0% | -$0.03+40.0% | -$0.03-50.0% | -$0.03+40.0% |
| EPS (Diluted) | -$0.02 | -$0.030.0% | -$0.04-33.3% | -$0.02 | -$0.020.0% | -$0.03+40.0% | -$0.03-50.0% | -$0.03+40.0% |
| Diluted Shares (Avg) | 16M | 16M+26.3% | N/A | 16M | 16M+41.6% | 13M+12.1% | N/A | 11M0.0% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
ACUT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6M-0.5% | $1.5M-0.1% | $1.5M+2947.0% | $1.6M+1415.4% | $1.6M+1055.3% | $1.6M+2943.9% | $51K-62.0% | $104K-59.7% |
| Current Assets | $106K-93.4% | $50K-96.8% | $49K-2.0% | $1.6M+1435.0% | $1.6M+1074.1% | $1.6M+3143.6% | $50K-61.2% | $102K-59.4% |
| Cash & Equivalents | $13K-58.8% | $12K-66.4% | $14K+176.0% | $14K-61.2% | $31K-32.0% | $36K+288.1% | $5K-76.5% | $37K-47.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.7M+38.0% | $5.4M+46.3% | $5.0M+47.2% | $4.5M+36.0% | $4.1M+37.2% | $3.7M+38.8% | $3.4M+49.8% | $3.3M+53.9% |
| Current Liabilities | $5.7M+38.0% | $5.4M+46.3% | $5.0M+47.2% | $4.5M+36.0% | $4.1M+37.2% | $3.7M+38.8% | $3.4M+49.8% | $3.3M+53.9% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | -$4.1M-62.5% | -$3.9M-79.6% | -$3.4M-2.7% | -$2.9M+8.9% | -$2.5M+12.1% | -$2.2M+17.7% | -$3.3M-56.9% | -$3.2M-69.4% |
| Retained Earnings | -$10.5M-18.6% | -$10.3M-21.3% | -$9.8M-21.9% | -$9.3M-21.1% | -$8.9M-21.0% | -$8.5M-20.1% | -$8.0M-23.1% | -$7.7M-22.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ACUT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$249K-1253.8% | -$374K-28.9% | $22K+5300.2% | -$604K-177.2% | $22K+110.3% | -$290K-22.3% | $414+100.1% | -$218K+38.0% |
| Depreciation & Amortization | N/A | N/A | $0-100.0% | $0-100.0% | $105-88.4% | $313-65.5% | $9070.0% | $9070.0% |
| Stock-Based Compensation | N/A | $15K-16.3% | N/A | $0 | $0 | $18K-0.3% | N/A | $0-100.0% |
| Financing Cash Flow | $250K+1038.0% | $372K+15.8% | -$23K+29.7% | $587K+181.0% | -$27K-110.8% | $322K+42.7% | -$32K-113.2% | $209K-30.8% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
ACUT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -256.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -256.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -15.7%+9.2pp | -31.4%-3.0pp | N/A | -25.4%+290.7pp | -24.9%+174.3pp | -28.4% | N/A | -316.1%-83.7pp |
| Current Ratio | 0.02-0.4x | 0.01-0.4x | 0.010.0x | 0.35+0.3x | 0.39+0.3x | 0.42+0.4x | 0.010.0x | 0.03-0.1x |
| Asset Turnover | 0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$3.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ACCUSTEM SCIENCES INC ACUT | FY2025 | N/A | -$1.8M | N/A | $2.6M | — |
| Harvard Apparatus Regenerative Technology Inc. HRGN | FY2025 | $704K | -$6.9M | N/A | $41.3M | — |
| Provectus Biopha PVCT | FY2025 | $336K | N/A | N/A | $24.8M | — |
Where ACCUSTEM SCIENCES INC Ranks
Frequently Asked Questions
Is ACCUSTEM SCIENCES INC profitable?
No, ACCUSTEM SCIENCES INC (ACUT) reported a net income of -$1.8M in fiscal year 2025.
What is ACCUSTEM SCIENCES INC's EBITDA?
ACCUSTEM SCIENCES INC (ACUT) had EBITDA of -$1.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ACCUSTEM SCIENCES INC's operating cash flow?
ACCUSTEM SCIENCES INC (ACUT) recorded an outflow of $850K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ACCUSTEM SCIENCES INC's total assets?
ACCUSTEM SCIENCES INC (ACUT) had $1.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does ACCUSTEM SCIENCES INC spend on research and development?
ACCUSTEM SCIENCES INC (ACUT) invested $281K in research and development during fiscal year 2025.
What is ACCUSTEM SCIENCES INC's current ratio?
ACCUSTEM SCIENCES INC (ACUT) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is ACCUSTEM SCIENCES INC's return on assets (ROA)?
ACCUSTEM SCIENCES INC (ACUT) had a return on assets of -113.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ACCUSTEM SCIENCES INC's P/E ratio?
ACCUSTEM SCIENCES INC (ACUT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.6M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ACCUSTEM SCIENCES INC's price-to-sales ratio?
ACCUSTEM SCIENCES INC (ACUT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.6M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ACCUSTEM SCIENCES INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ACCUSTEM SCIENCES INC (ACUT) held $14K in cash, cash equivalents and investments, and reported an operating cash outflow of $850K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is ACCUSTEM SCIENCES INC's debt-to-equity ratio negative or not reported?
ACCUSTEM SCIENCES INC (ACUT) has negative shareholder equity of -$3.4M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is ACCUSTEM SCIENCES INC's Piotroski F-Score?
ACCUSTEM SCIENCES INC (ACUT) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ACCUSTEM SCIENCES INC's earnings high quality?
ACCUSTEM SCIENCES INC (ACUT) reported a net loss of $1.8M while operations used $850K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.